KALV - KalVista Pharma Debt to Book Capitalization Ratio
This price chart for KalVista Pharmaceuticals (KALV) illustrates the efficiency of distributing orphan drugs through an extensive warehouse network, which ensures high margins. Meanwhile, KalVista Pharmaceuticals (KALV) remains in the development stage, generating no profit and spending on R&D, which is recorded at 0.00. The business is also implementing AI to discover treatments for edema, combining synthesis automation with medical expertise.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_KALV_-_KalVista-Pharmaceuticals_-_Debt-to-Net-Assets-Ratio "KalVista Pharmaceuticals - KALV Debt to Book Capitalization Ratio (period 07/04/2022 - 06/21/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for KalVista Pharma (KALV)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Total Debt to Equity Ratio KalVista Pharmaceuticals|KALV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital KalVista Pharmaceuticals Inc|KALV - Company Total Debt Obligations|Debt to Book Capitalization Ratio KalVista Corp|KALV - Company Long-Term Liabilities|Company Short-Term Debt KalVista Pharmaceuticals
Summary company analytics:KalVista Pharmaceuticals (KALV)
This indicator determines the ratio of total debt obligations to book capitalization, allowing investors to assess the business's financial resilience to external shocks without market noise. By analyzing the trend of the debt-to-book capitalization ratio, one can understand how effectively KalVista Pharmaceuticals (KALV) balances leveraged capital with the development of innovative oral medications for the treatment of hereditary angioedema.
Who KalVista Pharmaceuticals competes with
Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Zenas Bio - Debts to Book Value|Immunome Corp - Debt to Book Capitalization Ratio|GOSS - Debts to Book Capitalization|SEPN: Debts to Book Capitalization|PVLA (pieris.com) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Savara|Debt to Book Capitalization Ratio Rigel Pharma (RIGL)|Debt to Book Value AnaptysBio Corp (ANAB)|Debt to Book Capitalization Ratio Astria Corp (ATXS)|Debts to Book Capitalization ENGN|RAPT Therapeutics Inc. - Debts to Net Assets|Debt to Book Capitalization Ratio JBIO (Aerovate)|Aclaris Therapeutics Inc. (ACRS) - Debts to Net Assets|KYTX - Debt to Book Value|Tiziana Life Sciences, Ltd. (TLSA) - Debt to Book Capital|CABA (Cabaletta Bio, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization ventyxbio.com (VTYX)|Theratechnologies (THTX) - Debt to Book Value|Debt to Net Assets Ratio AVTX (Avalo Therapeutics, Inc.)|Eledon (ELDN) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Agenus, Inc AGEN|Debts to Book Capitalization Climb Bio Inc (CLYM)|ZURA - Debt to Net Assets Ratio|ATYR: Debts to Book Capitalization|ADAG (Adagene Inc.) - Debts to Book Capitalization|IMA - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio STTK|Debt to Book Capitalization Ratio EQ (Equillium, Inc.)|Debt to Book Value connectbiopharm.com (CNTB)|Debts to Book Capitalization IMUX (Immunic)|Debts to Book Capitalization Atara Biotherapeutics, Inc. ATRA|IFRX: Debts to Book Capitalization|XFOR - Debt to Book Value|Debts to Book Capitalization ACET|Debts to Book Value Celularity|INMB (INmune Bio) - Debt to Book Value|Debts to Book Capitalization Barinthus Biotherapeutics PLC (BRNS)|Debt to Book Value Kezar Life Sciences, Inc|Debt to Book Capital SAB Biotherapeutics Inc (SABS)|Debts to Book Capitalization AKTX|Debts to Net Assets Enlivex Therapeutics Ltd ENLV|QTTB: Debts to Book Capitalization|GOVX - Debt to Book Value|EDSA: Debts to Book Capitalization|IBIO (iBio Corporation) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Carisma Therapeutics Inc|Debt to Book Capitalization Ratio XTLB|BOLT (Bolt Biotherapeutics) - Debt to Book Capitalization Ratio|Debts to Net Assets HCWB (hcwbiologics.com)|Debt to Book Capitalization Ratio APVO (Aptevo Therapeutics Inc.)|Debts to Book Capitalization AIM ImmunoTech, Inc. AIM|Aditxt Corp - Debts to Book Capitalization|GRI: Debts to Book Capitalization|XORTX Therapeutics (XRTX) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Vyome Holdings Inc.|Debt to Book Value Revelation Bio|Debt to Book Capitalization Ratio INDP|SCNI - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio calcimedica.com (CALI)|Debts to Book Capitalization Affimed N.V.|Debt to Net Assets Ratio Allakos Inc ALLK|HOOKIPA - Debts to Book Capitalization|IGMS: Debts to Book Capitalization|Debt to Book Capitalization Ratio iTeos Therapeutics ITOS|OCEA (oceanbiomedical.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio TCBP|Debt to Book Value Third Harmonic Bio Inc.